DL-Threonine
(Synonyms: DL-苏氨酸) 目录号 : GC60783
DL-Threonine是一种必需氨基酸，可用于腿溃疡的研究。
Cas No.:80-68-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
DL-Threonine, an essential amino acid, has the potential to treat hypostatic leg ulceration[1].
[1]. Harvey SG, et al. L-cysteine, glycine and dl-threonine in the treatment of hypostatic leg ulceration: a placebo-controlled study. Pharmatherapeutica, 01 Jan 1985, 4(4):227-230.
| Cas No. | 80-68-2 | SDF | |
| 别名 | DL-苏氨酸 | ||
| Canonical SMILES | N[C@@H]([C@H](O)C)C(O)=O | ||
| 分子式 | C4H9NO3 | 分子量 | 119.12 |
| 溶解度 | H2O : 100 mg/mL (839.49 mM; Need ultrasonic); DMSO : < 1 mg/mL (insoluble or slightly soluble) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 8.3949 mL | 41.9745 mL | 83.949 mL |
| 5 mM | 1.679 mL | 8.3949 mL | 16.7898 mL |
| 10 mM | 0.8395 mL | 4.1974 mL | 8.3949 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Conversion of DL-Threonine, D-threonine and 2-oxobutyrate into propionate and 2-hydroxybutyrate by Fusobacterium species
Lett Appl Microbiol 1997 Nov;25(5):371-4.PMID:9418075DOI:10.1046/j.1472-765x.1997.00245.x.
The present investigation examined DL-Threonine, D-threonine and 2-oxobutyrate conversion into propionate and 2-hydroxybutyrate by various type strains and clinical isolates of Fusobacterium. Except for Fus. naviforme, the type strains were able to produce varying degrees of propionate and/or 2-hydroxybutyrate from DL-Threonine. Additionally, D-threonine was converted into an equimolar amount of propionate by Fus. necrophorum subsp. necrophorum, Fus. nucleatum subsp. nucleatum and Fus. varium, and to a lower but significant amount by Fus. mortiferum and Fus. perfoetens. However, the level of propionate remained unchanged for Fus. nucleatum subsp. fusiforme, Fus. nucleatum subsp. vincentii, Fus. naviforme, Fus. necrophorum subsp. funduliforme, Fus. gonidiaforme and Fus. russii. 2-Oxobutyrate was fermented to propionate by all type strains, although Fus. russii reduced it mainly to 2-hydroxybutyrate. Thus, an attempt was made to make use of these features in order to identify clinical isolates.
Crystallisation from a Water-in-Oil Emulsion as a Route to Enantiomer Separation: The Case of DL-Threonine
Chemistry 2016 Jan 4;22(1):74-8.PMID:26577229DOI:10.1002/chem.201503061.
The use of crystalliation as a means of separating enantiomers is well known. The utility of commonly applied seeding approaches is limited by the ultimate crystallisation of the antipode. Here we demonstrate how the combination of colloid science and crystal chemistry can lead to an emulsion based process yielding robust separation of a purified solid and impure liquid phases with ultimate product ee of up to 90 %. Threonine is used as a model to demonstrate the viability of the method but it is clear that extension to include, for example, simultaneous racemisation within the disperse phase is easily possible and would transform this from a separation to a preparation process.
Determination of Hepatoma-Associated DL-Amino Acids Enantiomers by RP-HPLC with Fluorescence Detector: Application in Patients with Hepatocellular Carcinoma
Ann Clin Lab Sci 2018 Jul;48(4):490-495.PMID:30143491doi
Background: Amino acids are increasingly being recognized as important signaling molecules in the pathogenesis of many diseases. We aim to establish a reversed-phase high-performance liquid chromatography with fluorescence detector (RP-HPLC-FLD) method for determination and quantification of hepatoma-associated DL-amino acids and to explore the relationship between amino acid concentrations and hepatocellular carcinoma (HCC). Methods: In this work, O-phthaldialdehyde (OPA) and N-isobutyryl-L-cysteine (NAC) served as the pre-column derivatization reagents which significantly shortened the detection time and improved the detection sensitivity. Chromatographic determination was achieved using a programmed gradient elution with a flow rate of 1.0 mL/min. The eluted solution was monitored by a fluorescence detector with an excitation wavelength at 350 nm and an emission wavelength at 450 nm. Under the optimum conditions, an excellent quantification of DL-Threonine, alanine, tyrosine, valine, methionine and phenylalanine was achieved. Results: Total analysis time was shortened to less than 25 min for one plasma sample and the linearity, recovery, intra- and inter-day precision were all meet the detection requirements of the DL-amino acids enantiomers in human plasma samples. Conclusions: The developed method demonstrates that DL-Threonine, alanine, tyrosine, valine and methionine obtained from HCC patients' plasma samples have a close relationship with HCC. The method would be a potentially alternative tool for DL-amino acids detection in clinical samples.
L-cysteine, glycine and DL-Threonine in the treatment of hypostatic leg ulceration: a placebo-controlled study
Pharmatherapeutica 1985;4(4):227-30.PMID:3933019doi
A randomized, double-blind, placebo-controlled trial was carried out in 22 patients with hypostatic leg ulceration. Patients were treated topically with either a cream containing the amino acids l-cysteine, glycine and DL-Threonine or the cream base alone (placebo). Most patients had their leg ulcers treated and dressed 3-times per week for 12 weeks. Clinical assessments were conducted at weekly intervals and data from 21 of the 22 patients were available for statistical analysis. The results revealed that the degree of healing and decrease of pain were significantly better in the group of patients receiving the amino acid combination. It would appear from this study that l-cysteine, glycine and DL-Threonine in combination are of value in promoting would healing in hypostatic leg ulceration.
Optical Resolution by the Replacing Crystallization of DL-Threonine with L-Alanine as an Optically Active Cosolute
Biosci Biotechnol Biochem 1999;63(12):2212-5.PMID:27373922DOI:10.1271/bbb.63.2212.
DL-Threonine (DL-Thr) was optically resolved by replacing crystallization with L-alanine (L-Ala) as an optically active cosolute. D-Thr was preferentially crystallized from a supersaturated aqueous solution of DL-Thr in the presence of L-Ala. Optical resolution was successfully achieved to afford D-Thr with an optical purity of 96-98% and L-Thr of 91-95%. The partially resolved D- and L-Thr were recrystallized from water, taking account of the solubility of DL-Thr, to efficiently yield both enantiomers in an optically pure form.